Identification and functional characterization of udp-glucuronosyltransferases UGT1A8* 1, UGT1A8* 2 and UGT1A8* 3

Pharmacogenetics

Volumn 12, Issue 4, 2002, Pages 287-297

  Huang, Yue Hua ^a   Galijatovic, Alema ^a   Nguyen, Nghia ^a   Geske, Donald ^a   Beaton, Deirdre ^a   Green, Judith ^a   Green, Mark ^a   Peters, Wilbert H ^a   Tukey, Robert H ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Drug metabolism; Glucuronidation; Pharmacogenomics; Polymorphism

Indexed keywords

GLUCURONOSYLTRANSFERASE; COMPLEMENTARY DNA; DNA; MESSENGER RNA; PRIMER DNA; UDP GLUCURONOSYLTRANSFERASE, UGT1A8; UDP-GLUCURONOSYLTRANSFERASE, UGT1A8;

AMINO ACID SUBSTITUTION; ARTICLE; CELL COMPARTMENTALIZATION; DNA TEMPLATE; DRUG METABOLISM; ENZYME ANALYSIS; GENE LOCUS; GENETIC ANALYSIS; GENETIC POLYMORPHISM; GENETIC TRANSFECTION; GLUCURONIDATION; HUMAN; HUMAN CELL; MOLECULAR CLONING; PHARMACOGENETICS; PRIORITY JOURNAL; BLOOD; CELL LINE; CHEMISTRY; COLON; ENZYMOLOGY; EXON; GENETIC TRANSCRIPTION; GENETICS; GENOTYPE; ISOLATION AND PURIFICATION; LIVER; METABOLISM; PHYSIOLOGY; PLASMID; POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SITE DIRECTED MUTAGENESIS; WESTERN BLOTTING;

BLOTTING, WESTERN; CELL LINE; CLONING, MOLECULAR; COLON; DNA; DNA PRIMERS; DNA, COMPLEMENTARY; EXONS; GENOTYPE; GLUCURONOSYLTRANSFERASE; HUMAN; LIVER; MUTAGENESIS, SITE-DIRECTED; PLASMIDS; POLYMERASE CHAIN REACTION; POLYMORPHISM (GENETICS); REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SUPPORT, U.S. GOV'T, P.H.S.; TRANSCRIPTION, GENETIC; TRANSFECTION; HUMANS; POLYMORPHISM, GENETIC;

EID: 0036016310     PISSN: 0960314X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008571-200206000-00004     Document Type: Article

References (41)

1. Human UDP-glucuronosyltransferases: Metabolism, expression, and disease
2. Genetic multiplicity of the human UDP-glucuronosyltransferases and regulation in the gastrointestinal tract
3. Differential expression of the UGT1A locus in human liver, biliary and gastric tissue. Identification of UGT1A7 and UGT1A10 transcripts in extrahepatic tissue
4. Expression of the UDP-glucuronosyltransferase 1A locus in human colon. Identification and characterization of the novel extrahepatic UGT1A
5. Polymorphic gene expression and interindividual variation of UDP-glucuronosyltransferase activity in human small intestine
6. UDP-glucuronosyltransferase activity in human liver and colon
7. Drug-mediated toxicity caused by genetic deficiency of UDP-glucuronosyltransferases
8. Interindividual variability in the glucuronidation of (S) oxazepam contrasted with that of (R) oxazapam
9. Preclinical and clinical development of cyclin-dependent kinase modulators
10. In vitro glucuronidation of the cyclin-dependent kinase inhibitor flavopiridol by rat and human liver microsomes: Involvement of UDP-glucuronosyltransferases 1A1 and 1A9
11. Flavopiridol metabolism in cancer patients is associated with the occurrence of diarrhea
12. Bioactivation of the anticancer agent CPT-11 to SN-38 by human hepatic microsomal carboxylesterases and the in vitro assessment of potential drug interactions
13. Clinical pharmacology of camptothecins
14. Human liver UDP-glucuronosyltransferase isoforms involved in the glucuronidation of 7-ethyl-10-hydroxycamptothecin
15. Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes
16. Glucuronidation of 7-ethyl-10-hydroxycamptothecin (SN-38) by the human UDP-glucuronosyltransferases encoded at the UGT1 locus
17. Pharmacogenetics of anticancer agents: Lessons from amonafide and irinotecan
18. Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: A pharmacogenetic analysis
19. Genetic link of hepatocellular carcinoma with polymorphisms of the UDP-glucuronosyltransferase UGT1A7 gene
20. Genetic lesions of bilirubin uridine-diphosphoglucuronate glucuronosyltransferase (UGT1A1) causing Crigler-Najjar and Gilbert syndromes: Correlation of genotype to phenotype
21. UDP-glucuronosyltransferase (UGT1A1* 28 and UGT1A6* 2) polymorphisms in Caucasians and Asians: Relationships to serum bilirubin concentrations
22. Genetic polymorphism in the human UGT1A6 (planar phenol) UDP-glucuronosyltransferase: Pharmacological implications
23. Structural heterogeneity at the UDP-glucuronosyltransferase 1 locus: Functional consequences of three novel missense mutations in the human UGT1A7 gene
24. Characterization and substrate specificity of UGT2B4 (E458): A UDP-glucuronosyltransferase encoded by a polymorphic gene
25. Genetic polymorphism of UDP-glucuronosyltransferase 2B7 (UGT2B7) at amino acid 268: Ethnic diversity of alleles and potential clinical significance
26. An allele-specific polymerase chain reaction method for the determination of the D85Y polymorphism in the human UDP-glucuronosyltransferase 2B15 gene in a case-control study of prostate cancer
27. Polymorphisms of the human UDP-glucuronosyltransferase (UGT) 1A7 gene in colorectal cancer
28. Tobacco carcinogen-detoxifying enzyme UGT1A7 and its association with orolaryngeal cancer risk
29. Characterization of two UDP-glucuronosyltransferases that are predominantly expressed in human colon
30. Glucuronidation of 2-hydroxyamino-1-methyl-6-phenylimidazo[4,5-b]pyridine by human microsomal UDP-glucuronosyltransferases: Identification of specific UGT1A family isoforms involved
31. Cloning and expression of human UDP-glucuronosyltransferase (UGT) 1A8
32. Studies on the substrate specificity of human intestinal UDP-glucuronosyltransferases 1A8 and 1A10
33. Characterization and tissue specificity of a monoclonal antibody against human uridine 5′-diphosphate-glucuronosyltransferase
34. Thirteen UDP-glucuronosyltransferase genes are encoded at the human UGT1 gene complex locus
35. Endoplasmic reticulum retention determinants in the transmembrane and linker domains of cytochrome P450 2C1
36. Small molecule modulators of cyclin-dependent kinases for cancer therapy
37. A phase II trial of the cyclin-dependent kinase inhibitor flavopiridol in patients with previously untreated stage IV non-small cell lung cancer
38. Mechanism of indinavir-induced hyperbilirubinemia
39. Flavopiridol inactivates P-TEFb and blocks most RNA polymerase II transcription in vivo
40. Regulation and function of family 1 and family 2 UDP-glucuronosyltransferase genes (UGT1A, UGT2B) in human oesophagus
41. Polymorphic expression of the UDP-glucuronosyltransferase UGT1A gene locus in human gastric epithelium